| Term | Definition |
|---|---|
| Acellular vaccine |
A vaccine that may contain cellular material but does not contain complete cells. |
| ACIP |
Advisory Committee on Immunization Practices. |
| Acquired immunity |
A passive immunization, which is defined as the transfer of active antibodies from an immunized individual (like a mother) to a non-immunized one (her baby). |
| Adjuvant |
Substance that is able to increase the period and/or the maturation of the immune response. |
| Adverse event (AE) |
Any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. |
| AFP (acute flaccid paralysis) |
Loss of muscle tone and decrease or absence of tendon reflexes in limbs, either due to polio or not |
| Allergy |
Abnormal reaction or increased sensitivity to certain antigens called allergens (e.g. eggs or pollens), which are not necessarily harmful in itself. After contact with this allergen, IgE massive amounts production is induced. Those immunoglobulins then active basophils and mast cells that release further chemicals, included histamine and prostaglandins. This in turn leads to an exaggerated inflammatory process. |
| Anaphylaxis |
An acute allergic reaction, which affects the whole body and requires immediate medical attention. |
| antibodies |
Are produced by the human body to fight a specific infection |
| Antibody |
Is produced by the human body to fight a specific infection |
| Antigen |
The part of a virus, bacteria or fungi (known as microbes) which causes the human body to react and activate the disease protection mechanism. It is usually part of the coating of the microbe. Antigen’s are unique to specific diseases |
| Antigenic drift |
Minor change in genetic material of microorganisms that modifies their antigenicity. Antigenic drift occurs naturally and more rapidly in RNA viruses (e.g. influenza or HIV viruses). |
| Antigenic shift |
Mutation in the genetic material of microorganisms such as viruses, resulting in novel strains. Antigenic shift in influenza viruses can be associated with human pandemics, in population immunologically naïve to the new strain. |
| Antigenicity |
Ability to induce an immune response. |
| Asymptomatic (“healthy”) carriers |
People infected by a pathogen without bearing any symptoms. However, they can transmit the pathogen. |
| Attenuation |
How to make microorganisms weaker so that they would not cause disease, but still protect against the real, dangerous germ. |
| B cells (or B lymphocytes) |
Cells that are produced by the bone marrow which, when stimulated by an antigen, become either a memory cell or a plasma cell (plasmocyte) that produces antibodies against that antigen. |
| B-cell |
B-cell lymphocytes make antibodies |
| Bacteria |
Independent organisms capable of multiplying autonomously. |
| Basophils |
Cells that release a variety of mediators in order to stimulate the inflammatory process (increase the blood flow in the area). |
| BCG |
The vaccine against Mycobacterium tuberculosis, which bears the name of its discoverers, Albert Calmette and Camille Guérin. |
| Biofermenters |
Bio-fermentor technology is the most efficient method of producing uniform quality, low cost pharmaceuticals where large amounts of active ingredient are required. |
| Biosafety level 3 (BSL-3) |
Series of work practices, safety equipment, and facilities considered appropriate for agents that may be transmitted by the respiratory tract and cause serious infection (e.g. anthrax). |
| CDC |
United States Centers for Disease Control and Prevention |
| Cellular response |
Also known and cell-mediated immunity, cellular response refers to an immune response that involves the activation of macrophages, natural killer cells, antigen-specific cytotoxic T-lymphocytes, and the release of various cytokines in response to an antigen. |
| Chemotaxis |
Increases directional migration of cells particularly in response to concentration gradients of certain chemotactic factors. |
| Clinical testing/research |
Before a drug or medication is licensed it has to be tested for safety and efficacy (to see whether it produces the desired protection) on smaller groups of humans. This is called clinical testing or research. |
| CMI |
Cell mediated immunity. |
| CNS |
Central nervous system. |
| Commensal bacteria |
Bacteria that are natural inhabitants of the human body. |
| Complement |
A group of serum proteins involved in the control of inflammation, the activation of phagocytes and the lytic attack on cell membranes. The system can be activated by interaction with the immune system. |
| Conjugation |
Natural phenomenon during which a bacterium can exchange genetic material with another bacterium, such as resistance to antibiotics. |
| Conjugation vaccine |
To attach a T-independent antigen to a carrier protein (or conjugate) that is recognized by the actors of the T-dependent pathway. Typical conjugate vaccines are polysaccharide vaccines. |
| Contact immunity |
Secondary immunization of contacts through the (protective) shedding of vaccine strains in stools. |
| Contagiousness |
How easily and quickly a disease, i.e. a microorganism, can spread from one person to another, depends on several factors. |
| Containment action plan |
Consists of 3 phases pre-eradication, post-eradication and global post-eradication. |
| Containment strategy |
Aims to locate every laboratory and vaccine manufacturer worldwide that stores wild poliovirus or potentially infectious material. |
| Continuous cell line |
Cells that are cultivated in flasks but still keep the inhibition of contact. |
| Cowpox |
See Smallpox. |
| Culling |
Selected killing of birds or poultry. |
| cVDPV (circulating VDPV) |
VDPV circulating in the environment that has regained the capacity to cause paralytic polio and cause outbreaks. |
| Cytokines |
Cytokines are any of a number of substances that are secreted by specific cells of the immune system which carry signals locally between cells, and thus have an effect on other cells. |
| Cytotoxic T-cells |
Type of T lymphocytes (mostly CD8) responsible for lysing target cells and for killing virus infected cells. |
| DEV |
Duck embryo cell vaccine (rabies). |
| DNA |
DNA is a double-stranded molecule held together by weak bonds between base pairs of nucleotides. The four nucleotides in DNA contain the bases adenine (A), guanine (G), cytosine (C), and thymine (T). DNA is a nucleic acid. |
| Effectiveness of a vaccine |
Ability to reduce the incidence of disease in real-life conditions. Vaccine effectiveness will be determined after use of the vaccine in national immunisation programmes. |
| Efficacy of a vaccine |
Ability to reduce the incidence of disease as measured in specific clinical studies. |
| ELISA (Enzyme-Linked Immunosorbent Assay |
In vitro test for the detection/dosage of the antibody or antigen, using specific antibodies conjugates to an enzyme (usually phosphatase or peroxydase). |
| Endemic |
Disease (or agent) prevalent in population or geographic area at all times, at a relatively constant, predictable levels. |
| Endotoxins |
Liberated molecules within the infected cells when the bacterium is destroyed. |
This section provides relevant evidence-based information for healthcare workers, programme managers, and policy makers. |
This section provides a guide for parents wishing to find about vaccines, how they work, when to vaccinate your child, and answer some of your frequently asked questions. CLICK HERE TO FIND OUT MORE |